Overview

A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients

Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to learn about the effects of the medication ixazomib in participants with scleroderma/systemic sclerosis including its safety and tolerability, its effects on skin, lungs and other organs, and its effects on overall health and quality of life.
Phase:
Phase 2
Details
Lead Sponsor:
W. Leroy Griffing
Treatments:
Ixazomib